In vivo NKG2A blockade using a monoclonal antibody was shown to enhance anti-tumor immunity by potentiating the cytotoxic effector functions of both NK and CD8+ T-cells in a syngeneic model of B-cell lymphoma [57]. Here, KLRC1 is linked to B-cell non-Hodgkin lymphoma.